{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:53:55Z","timestamp":1791298435352,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13365-026-01340-8","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:25Z","timestamp":1787838025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and multilevel meta-analysis of preclinical survival outcomes of Zika virus\u2013based oncolytic therapy in glioblastoma"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8317-2817","authenticated-orcid":false,"given":"Arthur","family":"Carib\u00e9 Sena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7162-7534","authenticated-orcid":false,"given":"M\u00e1rcio Igor","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-5950","authenticated-orcid":false,"given":"Vin\u00edcius","family":"Pinto Costa Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Miranda de Avellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"25","key":"1340_CR7","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"key":"1340_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag037","author":"KS Cashman","year":"2026","unstructured":"Cashman KS, Mistry AM, Kesarwani A, De Andrade Costa A, Daneshmand J, Rehman HU et al (2026) Oncolytic Zika virus therapy leverages CCR2\u2009+\u2009monocytes to boost anti-glioblastoma T cell responses. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noag037","journal-title":"Neuro Oncol"},{"issue":"5","key":"1340_CR18","doi-asserted-by":"publisher","first-page":"e01683","DOI":"10.1128\/mBio.01683-18","volume":"9","author":"Q Chen","year":"2018","unstructured":"Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y et al (2018) Treatment of human glioblastoma with a live attenuated Zika virus vaccine candidate. mBio 9(5):e01683\u2013e01618. https:\/\/doi.org\/10.1128\/mBio.01683-18","journal-title":"mBio"},{"key":"1340_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.omto.2022.01.011","volume":"24","author":"L Chen","year":"2022","unstructured":"Chen L, Zhou C, Chen Q, Shang J, Liu Z, Guo Y et al (2022) Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Mol Ther Oncolytics 24:522\u2013534. https:\/\/doi.org\/10.1016\/j.omto.2022.01.011","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"1340_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232858","volume":"15","author":"AT Crane","year":"2020","unstructured":"Crane AT, Chrostek MR, Krishna VD, Shiao M, Toman NG, Pearce CM et al (2020) Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells. PLoS One 15(10):e0232858. https:\/\/doi.org\/10.1371\/journal.pone.0232858","journal-title":"PLoS One"},{"issue":"20","key":"1340_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010996","volume":"22","author":"MG Francipane","year":"2021","unstructured":"Francipane MG, Douradinha B, Chinnici CM, Russelli G, Conaldi PG, Iannolo G (2021) Zika virus: a new therapeutic candidate for glioblastoma treatment. Int J Mol Sci 22(20):10996. https:\/\/doi.org\/10.3390\/ijms222010996","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1340_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192384","volume":"12","author":"GJ Garcia","year":"2023","unstructured":"Garcia GJ, Chakravarty N, Paiola S, Urena E, Gyani P, Tse C et al (2023) Differential susceptibility of ex vivo primary glioblastoma tumors to oncolytic effect of modified Zika virus. Cells 12(19):2384. https:\/\/doi.org\/10.3390\/cells12192384","journal-title":"Cells"},{"issue":"12","key":"1340_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102509","volume":"6","author":"AJ Hirsch","year":"2025","unstructured":"Hirsch AJ, de Andrade Costa A, German C, Parkins CJ, Smith JL, Russler-Germain E et al (2025) Intracranial injection of genetically modified, mosquito non-transmissible Zika virus: safety in primates and ramifications for brain tumor therapy. Cell Rep Med 6(12):102509. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102509","journal-title":"Cell Rep Med"},{"key":"1340_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"1340_CR19","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1158\/0008-5472.CAN-17-3201","volume":"78","author":"C Kaid","year":"2018","unstructured":"Kaid C, Goulart E, Caires-J\u00fanior LC, Araujo BHS, Soares-Schanoski A, Bueno HMS et al (2018) Zika virus selectively kills aggressive human embryonal CNS tumor cells in vitro and in vivo. Cancer Res 78(12):3363\u20133374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3201","journal-title":"Cancer Res"},{"key":"1340_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773191","volume":"13","author":"TV Komarasamy","year":"2022","unstructured":"Komarasamy TV, Adnan NAA, James W, Balasubramaniam VRMT (2022) Zika virus neuropathogenesis: the different brain cells, host factors and mechanisms involved. Front Immunol 13:773191. https:\/\/doi.org\/10.3389\/fimmu.2022.773191","journal-title":"Front Immunol"},{"issue":"24","key":"1340_CR5","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2217\/fon-2022-0440","volume":"18","author":"UM Lauer","year":"2022","unstructured":"Lauer UM, Beil J (2022) Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 18(24):2713\u20132732. https:\/\/doi.org\/10.2217\/fon-2022-0440","journal-title":"Future Oncol"},{"issue":"8","key":"1340_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1340_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144619","volume":"6","author":"S Nair","year":"2021","unstructured":"Nair S, Mazzoccoli L, Jash A, Govero J, Bais SS, Hu T et al (2021) Zika virus oncolytic activity requires CD8\u2009+\u2009T cells and is boosted by immune checkpoint blockade. JCI Insight 6(1):e144619. https:\/\/doi.org\/10.1172\/jci.insight.144619","journal-title":"JCI Insight"},{"issue":"2","key":"1340_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ymthe.2024.01.006","volume":"32","author":"GM Novaes","year":"2024","unstructured":"Novaes GM, Lima C, Longo C, Machado PH, Silva TP, de O Olberg GG et al (2024) Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors. Mol Ther 32(2):440\u201356. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.006","journal-title":"Mol Ther"},{"key":"1340_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"9","key":"1340_CR23","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1177\/0271678X20943823","volume":"40","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M et al (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab 40(9):1769\u201377. https:\/\/doi.org\/10.1177\/0271678X20943823","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Suppl 4","key":"1340_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2025) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018\u20132022. Neuro-Oncol 27(Suppl 4):iv1\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noaf194","journal-title":"Neuro-Oncol"},{"key":"1340_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.819363","volume":"16","author":"Z Qi","year":"2022","unstructured":"Qi Z, Long X, Liu J, Cheng P (2022) Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Front Cell Neurosci 16:819363. https:\/\/doi.org\/10.3389\/fncel.2022.819363","journal-title":"Front Cell Neurosci"},{"key":"1340_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01070-6","author":"E Quintana","year":"2026","unstructured":"Quintana E, Hernandez Palacios AM, Alonso-Curbelo D, Santhanam S, Nieto MM, Ikemura K et al (2026) Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-025-01070-6","journal-title":"Nat Cancer"},{"issue":"3","key":"1340_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL (2023) Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol 20(3):160\u2013177. https:\/\/doi.org\/10.1038\/s41571-022-00719-w","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1340_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"17","key":"1340_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713550","volume":"24","author":"R Tinnirello","year":"2023","unstructured":"Tinnirello R, Chinnici CM, Miceli V, Bus\u00e0 R, Bulati M, Gallo A et al (2023) Two sides of the same coin: normal and tumoral stem cells, the relevance of in vitro models and therapeutic approaches: the experience with Zika virus in nervous system development and glioblastoma treatment. Int J Mol Sci 24(17):13550. https:\/\/doi.org\/10.3390\/ijms241713550","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1340_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J et al (2022) Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630\u20131639. https:\/\/doi.org\/10.1038\/s41591-022-01897-x","journal-title":"Nat Med"},{"issue":"5","key":"1340_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/v12050579","volume":"12","author":"I Trus","year":"2020","unstructured":"Trus I, Berube N, Jiang P, Rak J, Gerdts V, Karniychuk U (2020) Zika virus with increased CpG dinucleotide frequencies shows oncolytic activity in glioblastoma stem cells. Viruses 12(5):579. https:\/\/doi.org\/10.3390\/v12050579","journal-title":"Viruses"},{"issue":"22","key":"1340_CR20","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T et al (2014) Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32(22):2380\u20132385. https:\/\/doi.org\/10.1200\/JCO.2014.55.2208","journal-title":"J Clin Oncol"},{"issue":"1","key":"1340_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04930-4","volume":"22","author":"CBL Victorio","year":"2024","unstructured":"Victorio CBL, Novera W, Ganasarajah A, Ong J, Thomas M, Wu J et al (2024) Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells. J Transl Med 22(1):126. https:\/\/doi.org\/10.1186\/s12967-024-04930-4","journal-title":"J Transl Med"},{"key":"1340_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1142172","volume":"13","author":"YY Wu","year":"2023","unstructured":"Wu YY, Sun TK, Chen MS, Munir M, Liu HJ (2023) Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front Cell Infect Microbiol 13:1142172. https:\/\/doi.org\/10.3389\/fcimb.2023.1142172","journal-title":"Front Cell Infect Microbiol"},{"key":"1340_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","volume":"15","author":"M Zheng","year":"2019","unstructured":"Zheng M, Huang J, Tong A, Yang H (2019) Oncolytic viruses for cancer therapy: barriers and recent advances. Mol Ther Oncolytics 15:234\u2013247. https:\/\/doi.org\/10.1016\/j.omto.2019.10.007","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"1340_CR10","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1084\/jem.20171093","volume":"214","author":"Z Zhu","year":"2017","unstructured":"Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC et al (2017) Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med 214(10):2843\u20132857. https:\/\/doi.org\/10.1084\/jem.20171093","journal-title":"J Exp Med"},{"issue":"2","key":"1340_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.stem.2019.11.016","volume":"26","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Mesci P, Bernatchez JA, Gimple RC, Wang X, Schafer ST et al (2020) Zika virus targets glioblastoma stem cells through a SOX2-integrin \u03b1v\u03b25 axis. Cell Stem Cell 26(2):187\u2013204e10. https:\/\/doi.org\/10.1016\/j.stem.2019.11.016","journal-title":"Cell Stem Cell"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-026-01340-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:35:00Z","timestamp":1791297300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-026-01340-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s13365-026-01340-8","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claude (Anthropic; Claude Sonnet 4.6) was used to assist with debugging the R and Python code, including identifying syntax errors, interpreting error messages, and suggesting code refactoring. The tool was not used to define the study design, select the statistical methods, modify the prespecified analytical strategy, interpret the results, or formulate the study conclusions.","order":1,"name":"Ethics","label":"Generative AI assistance in code development","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used previously published, non-identifiable data, including reconstructed pseudo-individual survival data from published Kaplan\u2013Meier curves; therefore, formal ethics approval was not required.","order":2,"name":"Ethics","label":"Ethics Approval <b>and Consent<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to the research, authorship, or publication of this paper.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"39"}}